Abstract Purpose: The study objective was to describe and compare changes in newly funded National Institutes of Health (NIH) tobaccorelated awards between fiscal year (FY) 2006 and FY2016.
Purpose
Tobacco control efforts have significantly reduced smoking rates over time, but tobacco use remains a leading cause of preventable morbidity and mortality in the United States. 1 Since 1995, only 1.1% to 1.3% of the total National Institutes of Health (NIH) budget has been allocated toward tobacco research; thus, this area of research has been historically underfunded compared to the funding allocated for other health problems (eg, obesity), despite causing a large disease burden. 2, 3 In recent years, there has been an emphasis on tobacco regulatory research. 1 The NIH is the leading funding source for biomedical and behavioral research worldwide. In 2016, of the $32.3 billion NIH budget, 80% was awarded through nearly 50 000 competitive grants to over 300 000 researchers in more than 2500 medical schools, universities, and other research institutions. 4 Given the competitive funding climate and the uncertainty of future federal budget allocations toward NIH funding, 5 it is important for applicants to understand the extent to which the NIH is funding new tobacco-related grants in order to continue important work in nicotine and tobacco research. This information will provide prospective applicants with the types and content areas of successfully funded tobacco-related NIH awards. The study objective was to describe and compare changes in newly funded NIH tobacco-related awards between 2 fiscal years (FYs), FY2006 and FY2016.
Methods

Design
All secondary data were accessed using the publicly available NIH Research Portfolio Online Reporting Tool (RePORT) database (https://report.nih.gov/), which includes reporting tools, reports, and data on research activities.
Sample
Similar to prior methodology, 3, 6 we used the RePORT Expenditures and Results tool (RePORTER; https://projectreporter. nih.gov/reporter.cfm) to search for new grants. We queried the FY "2006" and "2016" RePORTER database for "Admin" and "Funding" agency/institute/center that included "All NIH Institutes and Centers," "New" award types, "All" activity codes in "All" organization types (eg, research institutes) located in all "US States and Territories."
Measures
After reviewing "Project Terms" and "Project Titles" on RePORTER from a sample of funded awards during FY2006 and FY2016, 2 independent raters selected the following key terms for the text search: "Project Title," "tobacco," "smoking," "smoke," "SHS," "ETS," "TSE," "nicotine," "ENDS," "smoker," "electronic cigarette," "tobacco use," "secondhand smoke exposure," "environmental tobacco smoke," "tobacco smoke exposure," "smoke exposure," "e-cigarettes," "e-cigarette," "electronic cigarettes," "passive smoke exposure," "passive smoke," "thirdhand smoke," "cigarette," "cigarettes," "secondhand smoke," "tobacco smoke," and "electronic nicotine delivery."
While performing the search, we retrieved descriptive information on topic area by using the "Data & Visualize Circles" feature.
Analysis
We calculated frequency distributions overall and by NIH institute in FY2006 and FY2016 to determine the total number and percentage of new NIH grants for tobacco control, and total and median funding amounts for these grants. We accessed each institute's budget, with the exception of the US Food and Drug Administration (FDA) which was publicly unavailable. Additionally, the FDA did not begin to fund tobacco regulatory research until after the Family Smoking Prevention and Tobacco Control Act of 2009. 7 We computed the percentage of NIH funding allocated to new tobacco control awards by each institute and all institutes combined. We calculated percentage differences between FYs in total number of new tobacco-related grants, funding amounts, and percentage of funding allocated to new awards overall, and by institute. To calculate percentage differences, total funding amounts and institute budgets for grants in FY2006 were adjusted to FY2016 equivalent dollars using the US Bureau of Labor Statistics' 8 Consumer Price Index (CPI) inflation adjustment of 1.1947 .
Results
Overall, total NIH funding included in this study decreased by 12% in FY2016 compared to inflation-adjusted FY2006; $24 964 million (M; $20 896 M unadjusted) in FY2006 to $22 075 M in FY2016. 9 However, a total of 0.09% of the FY2006 budget was spent on new tobacco-related awards, while 0.25% of the FY2016 budget was spent on these awards (Table 1 ). In total, 230 new tobacco-related awards met inclusion criteria and underwent review: 86 in 2006 and 144 in 2016. There was a 67% increase in total number of new awards in FY2016 compared to FY2006. The data for new tobaccorelated awards per institute are presented in Table 1 . Inflation-adjusted median amount of funding per year increased from $201 522 in FY2006 compared to $254 711 in FY2016. Inflation-adjusted total funding for new tobaccorelated research increased by 154% from $22 076 987 in FY2006 compared to $56 015 931 in FY2016. Institutes increased the percentage of funding allocated to new tobacco-related awards by 187% overall between FYs (see Table 1 ). In FY2006, the top 3 funding institutes were: National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), and National Institute on Alcohol Abuse and Alcoholism (NIAAA). In FY2016, NIDA and NCI remained the top 2 funding institutes, and the National, Heart, Lung and Blood Institute (NHLBI) ranked third. These institutes increased the percentage of funding allocated to new tobacco-related awards (see Table 1 ).
Of the 86 tobacco-related studies funded in FY2006 and 144 projects funded in FY2016, research grants (R series) were the most frequent award types, accounting for 65 of the grants in FY2006 ($16 540 730) and 119 of the grants in FY2016 ($45 122 458; Figure 1 ). This represents an increase in number of R awards between FYs. In FY2006, the second most common award type was career development awards (K series) with 11 grants funded ($1 569 535), followed by 10 fellowship program awards (F series; $368 840). In contrast, in FY2016, the second most common award type was F awards (11; $501 270), followed by K awards (8; $1 239 762); the number of F awards slightly increased, but the number of K awards decreased between FYs. In FY2006, no cooperative agreement awards (U series), intramural program awards (Z series), or program project/center awards (P series) were awarded. In FY2016, there were 3 U series, ($4 028 659), 2 Z series ($1 817 580), and 1 P series ($3 306 202) awarded (see Figure 1) . Please see Supplemental Table 1 for information on funding opportunity announcements. Percentage changes calculated using FY2006 CPI inflation-adjusted total funding amount for new tobacco grants.
c Percentage changes calculated using FY2006 CPI inflation-adjusted institute budgets.
Smoking cessation was a common topic area and increased 64% from 39 grants in FY2006 to 64 grants in FY2016. Direct comparisons of all topic areas were not possible as descriptors changed in FY2006 and FY2016. In 2006, public health, nicotine addiction, and tobacco control were also the commonly funded topic areas. In 2016, other common topic areas were smoking exposure, young adults, and nicotine content.
Discussion
NIH funding is critically important to support the advancement of science in nicotine and tobacco research. Although there has been great progress in tobacco control over the past 50 years, a significant percentage of Americans continue to use tobacco. 1 In addition, the characteristics of tobacco users and the issues they face in quitting have changed, necessitating continued research in this area. 10 We found a 67% increase in number of new awards related to tobacco research in FY2016 compared to FY2006. Another key finding was a 154% increase in total amount of funding between FYs for tobacco-related research after CPI inflation adjustment. This could be attributed, in part, to the FDA beginning to fund regulatory research between time points; however, we were unable to track the differences in the FDA budget over time. In 2016, the NIH spent approximately $1.42 in new research for each American who is nicotine dependent and $0.18 for all Americans. This is in comparison to funding for cancer ($5589 M; $17.30 per American), cardiovascular health ($2108 M; $6.52 per American), and heart disease ($1289 M; $3.99 per American).
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Although the total NIH budget slightly decreased over time, the percentage of the total new tobacco-related grants increased by 187% between FYs. The number of institutes funding tobacco-related research increased over time, with 9 institutes funding new tobacco-related research in FY2006, and 14 in FY2016. Similar to prior research, 2 NIDA and NCI were the 2 top funding institutes, with a 106% and 231% respective increase in percentage of funds allocated to new tobaccorelated research between FYs. The third-ranked institute was NIAAA in FY2006 and NHLBI in FY2016; both institutes had a significant increase in total amount funded, but NHLBI had a much larger increase (þ884%) than NIAAA (þ184%), potentially due to a low base rate of new grants (n ¼ 3) funded in FY2006. Further, R grants were the most frequent award types funded. F awards slightly increased from 10 to 11 awards, but K awards decreased from 11 to 8 awards from FY2006 to FY2016. Tobacco-related U awards, Z awards, and P awards were funded in FY2016, but none were reported in FY2006. It is important to note that a possible reason for the difference in these awards is that only a few of these mechanisms are available each FY.
The only common topic area was smoking cessation with a 64% increase between FYs. The other topic areas differed from FY2006 (public health, nicotine addiction, tobacco control) to FY2016 (smoking exposure, young adults, and nicotine content). One potential explanation for the descriptive differences in topic areas is the introduction of e-cigarettes to the US market in 2007, leading to a substantial increase in use of this emerging product especially among youth and young adults.
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Another possible reason for the differences in topic areas between FYs is the Family Smoking and Prevention Tobacco Control Act. 7 This law gives the FDA authority to monitor and regulate tobacco product manufacturing, marketing, and distribution in order to reduce tobacco product-related risks and exposures, which requires restricted tobacco product marketing to youth, more visible warning labels on smokeless tobacco products and advertisements, and disclosure of tobacco product ingredients. 7 However, we were unable to directly compare FDA tobacco-related funding between FYs because the FDA was not funding tobacco-related regulatory research in FY2006. Further, despite substantial progress in smoke exposure reduction in the past 2 decades, one-fourth of Americans remain exposed to secondhand smoke. 13 Although these issues may explain the differences in most common topic areas funded between FYs, there is a possibility that the topic areas were added or changed by the NIH over time. 
Limitations
This study is not without limitations. While the keywords were limited to the project titles, grants could have been related to other disease burdens (eg, tobacco and alcohol) and not solely tobacco related. We were unable to provide differences between all topic areas since these differed between FYs. Despite this, smoking cessation will likely remain a common term as the majority of tobacco research focuses on treatment and tobacco control. We were unable to filter results by new investigator or early stage investigator status; this information would have been informative for those early in their career. Finally, our analyses focused solely on NIH funding and did not assess other potential funding sources.
Significance
Successfully funded tobacco-related research applications related to topic areas of interest are needed to decrease the health burden tobacco places on the United States. Future investigation is recommended to continue to assess funding for this critical scientific area over time. This investigation informs researchers on the types and content areas of new NIH-funded tobacco-related research awards.
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